PBH Stock Analysis: Prestige Brand Holdings | NYSE

Analgesics, Digestive Health, Feminine Care, Oral Care

Total Rating 39

Safety 64

Buy Signal -0.82

Drug Manufacturers - Specialty & Generic
Industry Rotation: +4.4

Market Cap: 2.14B
Avg Turnover: 28.6M

Risk 3d forecast

Volatility36.4%

VaR 5^th Pctl6.45%

VaR vs Median7.53%

Reward TTM

Sharpe Ratio-0.83

Rel. Str. IBD14.9

Rel. Str. Peer Group21.6

Character TTM

Beta0.185

Beta Downside0.317

Hurst Exponent0.478

Drawdowns 3y

Max DD49.75%

CAGR/Max DD-0.14

CAGR/Mean DD-0.41

EPS (Earnings per Share)

EPS CAGR: 0.89%
EPS Trend: 21.7%

Last SUE: 1.16
Qual. Beats: 1

Revenue

Rev. CAGR: -0.96%
Rev. Trend: -69.8%

Last SUE: 1.60
Qual. Beats: 1

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan -3.2% 17

Feb +4.8% 35

Mar +1.0% 5

Apr -1.1% 32

May -1.3% 28

Jun +2.6% 35

Jul -0.3% 5

Aug -5.6% 20

Sep -3.2% 47

Oct -0.1% 8

Nov +4.2% 28

Dec +1.4% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: PBH Prestige Brand Holdings

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a US-based mid-cap healthcare company that develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products across North America, Australia, and other international markets. The company operates in two reporting segments: North American OTC Healthcare and International OTC Healthcare, reflecting its geographic diversification in the consumer health space. The OTC consumer healthcare sector is generally characterized by stable, recession-resistant demand driven by brand loyalty and repeat purchases of non-prescription remedies.

The company markets a broad portfolio of well-known OTC brands across categories including analgesics (BC, Goodys), baby care (Boudreauxs Butt Paste), oral care (Chloraseptic, DenTek, Ludens), eye care (Clear Eyes, TheraTears), womens health (Monistat, Summers Eve), digestive health (Gaviscon, Fleet), and other remedies such as Compound W, Debrox, Dramamine, Nix, Fess, and Hydralyte. This brand-heavy model is typical of the OTC pharmaceuticals sub-industry, where value is driven by consumer recognition and shelf placement rather than patented drug innovation.

Prestige sells its products through mass merchandisers, drug stores, food retailers, dollar stores, convenience stores, club stores, and e-commerce channels, leveraging a diversified distribution network that supports widespread product availability. Founded in 1996 and headquartered in Tarrytown, New York, the company was originally known as Prestige Brands Holdings, Inc. before rebranding to Prestige Consumer Healthcare Inc. in August 2018 to better reflect its focus on consumer health products.

Headlines to Watch Out For

North American OTC segment drives core revenue growth
Acquisition strategy expands brand portfolio with added leverage
Private label competition pressures pricing and margins

Piotroski VR-10 (Strict) 4.5

Net Income: 172.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.65 > 1.0
NWC/Revenue: 31.04% < 20% (prev 33.11%; Δ -2.06% < -1%)
CFO/TA 0.05 > 3% & CFO 249.4m > Net Income 172.0m
Net Debt (2.02b) to EBITDA (312.7m): 6.46 < 3
Current Ratio: 3.23 > 1.5 & < 3
Outstanding Shares: last quarter (47.6m) vs 12m ago -4.47% < -2%
Gross Margin: 53.26% > 18% (prev 56.18%; Δ -2.92% > 0.5%)
Asset Turnover: 27.62% > 50% (prev 32.64%; Δ -5.02% > 0%)
Interest Coverage Ratio: 6.08 > 6 (EBIT TTM 280.3m / Interest Expense TTM 46.1m)

Altman Z'' 2.99

A: 0.08 (Total Current Assets 496.8m - Total Current Liabilities 153.8m) / Total Assets 4.57b
B: 0.39 (Retained Earnings 1.78b / Total Assets 4.57b)
C: 0.07 (EBIT TTM 280.3m / Avg Total Assets 4.00b)
D: 0.72 (Book Value of Equity 1.92b / Total Liabilities 2.65b)
Altman-Z'' = 2.99 = A

Beneish M -2.86

DSRI: 1.13 (Receivables 187.4m/168.4m, Revenue 1.10b/1.12b)
GMI: 1.05 (GM 56.18% / 53.26%)
AQI: 1.04 (AQ_t 0.86 / AQ_t-1 0.82)
SGI: 0.99 (Revenue 1.10b / 1.12b)
TATA: -0.02 (NI 172.0m - CFO 249.4m) / TA 4.57b)
Beneish M = -2.86 (Cap -4..+1) = A

What is the price of PBH shares?

As of October 08, 2026, the stock is trading at USD 47.57 with a total of 460,851 shares traded. Over the past week, the price has changed by +3.71%, over one month by -4.46%, over three months by -5.65% and over the past year by -24.34%.

Current recommended Stop Loss: 45.50 (which is 4.4% or 1.5 ATR below the current price).

Is PBH a buy, sell or hold?

Prestige Brand Holdings has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy PBH.

StrongBuy: 4
Buy: 1
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the PBH price?

Analysts Target Price	67.8	42.5%

Prestige Brand Holdings (PBH) - Fundamental Data Overview as of 06 October 2026

Market Cap USD = 2.14b (2.14b USD * 1.0 USD.USD)
P/E Trailing = 12.6779
P/E Forward = 10.5485
P/S = 1.9406
P/B = 1.1797
P/EG = 1.5069
Revenue TTM = 1.10b USD
EBIT TTM = 280.3m USD
EBITDA TTM = 312.7m USD
Long Term Debt = 2.01b USD (from longTermDebt, last quarter)
Short Term Debt = 20.2m USD (from shortTermDebt, last quarter)
Debt = 2.11b USD (from shortLongTermDebtTotal, last quarter) + Leases 46.1m
Net Debt = 2.02b USD (calculated: Debt 2.11b - CCE 89.1m)
Enterprise Value = 4.16b USD (2.14b + Debt 2.11b - CCE 89.1m)
Interest Coverage Ratio = 6.08 (Ebit TTM 280.3m / Interest Expense TTM 46.1m)
EV/FCF = 17.70x (Enterprise Value 4.16b / FCF TTM 235.4m)
FCF Yield = 5.65% (FCF TTM 235.4m / Enterprise Value 4.16b)
FCF Margin = 21.30% (FCF TTM 235.4m / Revenue TTM 1.10b)
Net Margin = 15.57% (Net Income TTM 172.0m / Revenue TTM 1.10b)
Gross Margin = 53.26% ((Revenue TTM 1.10b - Cost of Revenue TTM 516.4m) / Revenue TTM)
Gross Margin QoQ = 51.25% (prev 50.02%)
Tobins Q-Ratio = 0.91 (Enterprise Value 4.16b / Total Assets 4.57b)
Interest Expense / Debt = 2.18% (Interest Expense 46.1m / Debt 2.11b)
Taxrate = 26.57% (62.2m / 234.3m)
NOPAT = 205.8m (EBIT 280.3m * (1 - 26.57%))
Current Ratio = 3.23 (Total Current Assets 496.8m / Total Current Liabilities 153.8m)
Debt / Equity = 1.10 (Debt 2.11b / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = 6.46 (Net Debt 2.02b / EBITDA 312.7m)
Debt / FCF = 8.59 (Net Debt 2.02b / FCF TTM 235.4m)
Total Stockholder Equity = 1.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.30% (Net Income 172.0m / Total Assets 4.57b)
RoE = 9.22% (Net Income TTM 172.0m / Total Stockholder Equity 1.86b)
RoCE = 7.24% (EBIT 280.3m / Capital Employed (Equity 1.86b + L.T.Debt 2.01b))
RoIC = 4.70% (NOPAT 205.8m / Invested Capital 4.38b)
WACC = 4.14% (E(2.14b)/V(4.25b) * Re(6.63%) + D(2.11b)/V(4.25b) * Rd(2.18%) * (1-Tc(0.27)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.28 | Cagr: -2.43%
[DCF] Terminal Value 73.61% ; FCFF base≈248.4m ; Y1≈223.9m ; Y5≈191.2m
[DCF] Fair Price = 21.68 (EV 3.05b - Net Debt 2.02b = Equity 1.03b / Shares 47.4m; r=8.35% [WACC [floored]]; 5y FCF grow -12.13% → 2.50% )
EPS Correlation: 21.66 | EPS CAGR: 0.89% | SUE: 1.16 | # QB: 1
Revenue Correlation: -69.79 | Revenue CAGR: -0.96% | SUE: 1.60 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.07 | Chg30d=+0.00% | Revisions=-25% | Analysts=7
EPS next Quarter (2026-12-31): EPS=1.24 | Chg30d=+0.00% | Revisions=-40% | Analysts=7
EPS current Year (2027-03-31): EPS=4.57 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+4.3% | GrowthRev=+17.0%
EPS next Year (2028-03-31): EPS=5.08 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+11.2% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -22% (up=2, down=4)